ACTRN12619000115134暂停未知
A multi-centre, patient and assessor-blinded, parallel groups, randomised controlled trial comparing restricted and liberal oxygen therapy with standard oxygen therapy in patients having major surgery
适应症
试验速览
- 阶段
- 未知
- 状态
- 暂停
- 入组人数
- 2,640
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patients undergoing non-cardiac surgery under general anaesthesia with an expected duration of at least 2 hours and anticipated in-hospital stay of at least 1 post-operative night
- •American Society of Anaesthesiologists Physical Status Classification (ASA) 3 or 4
排除标准
- •Current pregnancy
- •The treating clinicians consider that there is a specific indication for either liberal or restricted oxygen therapy in the perioperative period
- •Previously enrolled in the HOT-ROX study
研究者
相似试验
已完成
不适用
Comparison of efficacy and safety of Betesil® medicated plaster versus Daivobet®/Dovobet® ointment in the treatment of chronic plaque psoriasisChronic plaque psoriasisSkin and Connective Tissue DiseasesPsoriasisISRCTN34974208Institut Biochimique SA (IBSA) (Switzerland)300
已完成
3 期
Efficacy and safety of Institut Biochimique SA (IBSA) 0.1% betamethasone valerate (BMV) medicated plaster versus reference marketed product for the treatment of chronic plaque psoriasisISRCTN68864186Institut Biochimique SA (IBSA) (Switzerland)180
进行中（未招募）
不适用
Multicentre, prospective, assessor-blind, in parallel groups randomised and vs reference marketed product controlled confirmatory trial of the efficacy and safety of IBSA BMV medicated plaster for the treatment of chronic plaque psoriasischronic plaque psoriasisMedDRA version: 9.1Level: LLTClassification code 10033898Term: ParapsoriasisEUCTR2005-003050-96-ITIBSA180
进行中（未招募）
不适用
Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil, IBSA-Institut Biochimique S.A.) versus 50μg-0,5mg/g calcipotriol-betamethasone (dipropionate) ointment (Daivobet/Dovobet, LEO Pharmaceutical Products), in the treatment of chronic plaque psoriasis. - NDEUCTR2009-016969-28-ITIBSA INSTITUT BIOCHIMIQUE SA300
进行中（未招募）
1 期
Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil®, IBSA-Institut Biochimique S.A.) versus 50µg-0,5mg/g calcipotriol-betamethasone (dipropionate) ointment (Daivobet®/Dovobet®, LEO Pharmaceutical Products), in the treatment of chronic plaque psoriasis.EUCTR2009-016969-28-FRIBSA, Institut Biochimique SA